SCHEMBL6318909

SCHEMBL6318909

Cc1ccccc1-c1ccc(F)c([N+](=O)[O-])c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.49
HIF1A Q16665 1/20 0.49
HSD17B10 Q99714 1/20 0.49
VCAM1 P19320 1/20 0.46
MAPT P10636 3/20 0.46
LMNA P02545 2/20 0.46
HTT P42858 2/20 0.46
S1PR1 P21453 1/20 0.46
SMN1; SMN2 Q16637 2/20 0.43
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
ABCG2 Q9UNQ0 1/20 0.43
TSHR P16473 2/20 0.42
TDP1 Q9NUW8 1/20 0.42
CA12 O43570 1/20 0.41
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
CA9 Q16790 1/20 0.41
NQO1 P15559 1/20 0.41
PTGES O14684 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12117513 0.85 HSD17B10 (0.58) ALDH1A1HSD17B10MAPTLMNAS1PR1
SCHEMBL6320483 0.85 ALDH1A1 (0.53) ALDH1A1HIF1AHSD17B10VCAM1MAPT
SCHEMBL3270267 0.84 S1PR1 (0.56) ALDH1A1HIF1AHSD17B10MAPTLMNA
SCHEMBL16538292 0.82 TDP1 (0.57) ALDH1A1HIF1AVCAM1MAPTLMNA
SCHEMBL29655290 0.81 TDP1 (0.64) ALDH1A1HSD17B10MAPTLMNAS1PR1
SCHEMBL28258156 0.81 TDP1 (0.64) ALDH1A1HSD17B10MAPTLMNAS1PR1
SCHEMBL13309518 0.81 ALDH1A1 (0.59) ALDH1A1HSD17B10MAPTS1PR1SMN1; SMN2
SCHEMBL4405765 0.81 ALDH1A1 (0.53) ALDH1A1HIF1AMAPTLMNAHTT
SCHEMBL11739681 0.80 POLB (0.49) ALDH1A1HSD17B10MAPTLMNAHTT
SCHEMBL6314011 0.80 ITGB1 (0.51) ALDH1A1HIF1AHSD17B10VCAM1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6900214-B2 Cyano-substituted dihydropyrimidine compounds and their use to treat diseases BRISTOL-MYERS SQUIBB COMPANY (US) 2005-05-31 US disclosed
US-20050014810-A1 Use of substituted 2 phenylbenzimidazoles as medicaments BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2005-01-20 US disclosed
US-6809102-B2 FOR THERAPY OF PROLIFERATIVE DISEASES, SUCH AS CANCER; TO INTERRUPT MITOSIS BRISTOL-MYERS SQUIBB COMPANY 2004-10-26 US disclosed
US-20030008888-A1 Novel cyano-substituted dihydropyrimidine compounds and their use to treat diseases BRISTOL-MYERS SQUIBB COMPANY 2003-01-09 US disclosed
US-20020143026-A1 Cyano-substituted dihydropyrimidine compounds and their use to treat diseases BRISTOL-MYERS SQUIBB COMPANY 2002-10-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020143026-A1 Cyano-substituted dihydropyrimidine compounds and their use to treat diseases CCNB1, BUB1B, BUB1 ALDH1A1 980/4885HIF1A 1991/4885HSD17B10 1279/4885
US-20030008888-A1 Novel cyano-substituted dihydropyrimidine compounds and their use to treat diseases CCNB1, BUB1B, BUB1 ALDH1A1 1500/4885HIF1A 2542/4885HSD17B10 1516/4885
US-20050014810-A1 Use of substituted 2 phenylbenzimidazoles as medicaments GLP1R, GIPR, GCGR ALDH1A1 1506/4885HIF1A 489/4885HSD17B10 3796/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.